Flossbach Von Storch AG purchased a new position in Allergan plc (NYSE:AGN) in the 3rd quarter, HoldingsChannel reports. The institutional investor purchased 1,170 shares of the company’s stock, valued at approximately $223,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Thompson Siegel & Walmsley LLC lifted its position in Allergan by 3,032.4% during the second quarter. Thompson Siegel & Walmsley LLC now owns 877,740 shares of the company’s stock valued at $146,337,000 after acquiring an additional 849,719 shares during the last quarter. Renaissance Technologies LLC lifted its position in Allergan by 27,066.5% during the second quarter. Renaissance Technologies LLC now owns 787,828 shares of the company’s stock valued at $131,347,000 after acquiring an additional 784,928 shares during the last quarter. Mainstay Capital Management LLC ADV lifted its position in Allergan by 13,097.2% during the second quarter. Mainstay Capital Management LLC ADV now owns 675,039 shares of the company’s stock valued at $4,288,000 after acquiring an additional 669,924 shares during the last quarter. Janus Henderson Group PLC lifted its position in Allergan by 16.3% during the second quarter. Janus Henderson Group PLC now owns 4,778,699 shares of the company’s stock valued at $796,712,000 after acquiring an additional 668,343 shares during the last quarter. Finally, Orbimed Advisors LLC lifted its position in Allergan by 85.4% during the second quarter. Orbimed Advisors LLC now owns 1,286,205 shares of the company’s stock valued at $214,436,000 after acquiring an additional 592,600 shares during the last quarter. 77.55% of the stock is owned by hedge funds and other institutional investors.
AGN has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Allergan from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Credit Suisse Group set a $213.00 target price on shares of Allergan and gave the company a “buy” rating in a research report on Friday, July 13th. Wells Fargo & Co set a $240.00 target price on shares of Allergan and gave the company a “buy” rating in a research report on Thursday, July 19th. Cantor Fitzgerald set a $180.00 target price on shares of Allergan and gave the company a “hold” rating in a research report on Thursday, July 19th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $164.00 target price on shares of Allergan in a research report on Thursday, July 26th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the stock. Allergan has an average rating of “Buy” and an average price target of $210.18.
In other Allergan news, Director Joseph H. Boccuzi acquired 900 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were purchased at an average price of $190.59 per share, for a total transaction of $171,531.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of the business’s stock in a transaction dated Thursday, September 6th. The stock was acquired at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. Corporate insiders own 0.37% of the company’s stock.
Shares of Allergan stock opened at $165.21 on Wednesday. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32. Allergan plc has a 12-month low of $142.81 and a 12-month high of $197.00. The company has a market cap of $54.99 billion, a price-to-earnings ratio of 10.10, a P/E/G ratio of 1.29 and a beta of 1.31.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.04 by $0.21. Allergan had a net margin of 14.50% and a return on equity of 8.44%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.89 billion. During the same quarter in the prior year, the business posted $4.15 EPS. Allergan’s revenue for the quarter was down 3.0% compared to the same quarter last year. Research analysts forecast that Allergan plc will post 16.42 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Tuesday, November 13th will be paid a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a yield of 1.74%. Allergan’s payout ratio is 17.61%.
COPYRIGHT VIOLATION NOTICE: “1,170 Shares in Allergan plc (AGN) Acquired by Flossbach Von Storch AG” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/07/1170-shares-in-allergan-plc-agn-acquired-by-flossbach-von-storch-ag.html.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Featured Story: How to calculate compound interest
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.